It has been reported by Désiré et al. [76] on the identification in AD patients of blood-based transcriptomic signatures related to treatment response of EHT-0202 in a placebo-controlled, three-month, phase IIA study for estimating the exploratory efficacy, tolerability, and clinical safety of EHT-0202 (i.e., 80 and 40 mg twice a day) as adjunctive therapy to one cholinesterase inhibitor in mild-to-moderate AD individuals. This evidence concerns the gene BCHE and Alzheimer disease.